ClinicalTrials.Veeva

Menu

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

Novartis logo

Novartis

Status and phase

Terminated
Phase 2

Conditions

Peripheral Artery Disease

Treatments

Drug: Canakinumab (ACZ885)
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01731990
2012-001427-12
CACZ885M2201

Details and patient eligibility

About

This study was designed to assess the safety, tolerability and efficacy of ACZ885 on the leg artery structure and physical activity in patients with atherosclerotic peripheral artery disease and leg pain from walking.

Enrollment

38 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Must have a signed informed consent form.
  • Must be between the ages of 18 and 85
  • Must experience leg pain associated with walking and have an ankle brachial index between 0.40 and 0.9
  • Must be on stable aspirin and statin doses for at least 6 weeks
  • Blood pressure within ranges specified in the protocol
  • Able to communicate well with the Investigator and understand and comply with the study procedures

Key Exclusion Criteria:

  • Recent use of any other experimental drugs
  • Pregnant or nursing women
  • Women of child bearing potential unless willing to use contraception as detailed in the protocol
  • Cannot walk 15 meters (50 feet)
  • People on restricted medications as listed in the protocol
  • Any open or non-healing wounds with 3 months of study start or infection within 2 weeks or study start
  • Significant heart disease
  • Uncontrolled diabetes
  • Significant kidney or liver disease
  • Live vaccinations within 3 months of study start
  • History of untreated tuberculosis or active tuberculosis (TB)
  • Patients with metal in their body (excluded due to MRI scan) as detailed in the protocol.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

38 participants in 2 patient groups, including a placebo group

Canakinumab (ACZ885)
Experimental group
Description:
Monthly subcutaneous doses of Canakinumab 150 mg/1 mL for 12 months
Treatment:
Drug: Canakinumab (ACZ885)
Placebo
Placebo Comparator group
Description:
Monthly subcutaneous doses of placebo of Canakinumab 150 mg/1 mL for 12 months
Treatment:
Drug: Placebo

Trial contacts and locations

14

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems